Despite a median treatment time of 9.5 hours after stroke onset - more than twice the current therapeutic window - JX10 showed significantly better functional outcomes than placebo with no symptomatic intracranial hemorrhage events.
While individual treatments targeting neuroinflammation, oxidative stress, or mitochondrial dysfunction have historically disappointed in ALS trials, eight alternative treatments showing multi-mechanism effects warrant further investigation, according to a comprehensive review of 15 years of clinical data.